Constellation Pharmaceuticals (NASDAQ:CNST) announced its quarterly earnings data on Thursday. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.14), Fidelity Earnings reports.
Shares of CNST traded down $0.23 during midday trading on Friday, hitting $5.86. The company had a trading volume of 6,229 shares, compared to its average volume of 19,381. Constellation Pharmaceuticals has a 1 year low of $5.57 and a 1 year high of $12.21.
Several brokerages have recently issued reports on CNST. JPMorgan Chase & Co. began coverage on Constellation Pharmaceuticals in a research note on Monday, August 13th. They issued an “overweight” rating and a $17.00 price objective for the company. BMO Capital Markets began coverage on Constellation Pharmaceuticals in a research note on Monday, August 13th. They issued an “outperform” rating and a $19.00 price objective for the company. Oppenheimer set a $21.00 price objective on Constellation Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 1st. Zacks Investment Research cut Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 23rd. Finally, Cann began coverage on Constellation Pharmaceuticals in a research note on Monday, August 13th. They issued an “outperform” rating and a $21.00 price objective for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Constellation Pharmaceuticals presently has an average rating of “Buy” and an average price target of $17.15.
TRADEMARK VIOLATION WARNING: This report was originally published by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/11/10/constellation-pharmaceuticals-cnst-posts-quarterly-earnings-results-misses-estimates-by-0-14-eps.html.
Constellation Pharmaceuticals Company Profile
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.
Further Reading: Diversification For Individual Investors
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.